CLARITY PHARMACEUTICALS LTD

The S&P/ASX 200 Index slipped into the red, but Clarity Pharmaceuticals, Omni Bridgeway, Santana Minerals, and Vulcan Energy Resources saw gains. Clarity expanded its pipeline with a novel radiopharmaceutical. Omni Bridgeway entered a framework agreement with Ares Management Corporation. Santana Minerals benefited from New Zealand's Fast-track Approvals Bill. Vulcan Energy secured a €879 million debt commitment for its Lionheart Project.